Physician profile
Jason Moss
NPI 1235558149
$1,787.66
in general payments reported to CMS, 2019-2025
15 companies · $552 in 2025
The $552 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.68 · 2020: $93.78 · 2021: $226 · 2022: $308 · 2023: $175 · 2024: $415 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.74 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $542.67 | 2019-2025 | Dovato, Rukobia, Cabenuva |
| Merck Sharp & Dohme LLC | $327.08 | 2022-2025 | Dificid, Pifeltro, Zerbaxa |
| Abbvie INC. | $205.89 | 2022-2025 | |
| Insmed, INC. | $204.64 | 2020-2025 | Arikayce |
| Gilead Sciences, INC. | $145.76 | 2021-2025 | Veklury |
| Theratechnologies INC. | $71.65 | 2022-2025 | Egrifta, Trogarzo |
| Paratek Pharmaceuticals, INC. | $56.25 | 2024-2025 | Nuzyra |
| La Jolla Pharmaceutical Company | $55.24 | 2024-2025 | Xacduro, Zevtera |
| Shionogi INC | $42.81 | 2025 | Fetroja |
| Pfizer INC. | $33.11 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $27.46 | 2024-2025 | Rebyota |
| Janssen Biotech, INC. | $27.32 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $17.36 | 2025 | Vowst |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.31 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.